Maze Therapeutics, Inc. Common Stock share price logo

Maze Therapeutics, Inc. Common Stock

NASDAQ: MAZE

Small Cap

$24.50

-1.06

(-4.15%)

as on

Maze Therapeutics, Inc. Common Stock Stock Performance

as on May 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $24.16
    $25.75
    downward going graph

    1.39%

    Downside

    5.10%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.16
    $53.65
    downward going graph

    62.63%

    Downside

    118.98%

    Upside

    downward going graph

Maze Therapeutics, Inc. Common Stock share price movements today

Previous Close
$25.56
Open
$25.57
Volume
608.1K
Day's Low - High
$24.16 - $25.75
52 Week Low - High
$9.16 - $53.65

Maze Therapeutics, Inc. Common Stock Historical Returns

1 Month Return
-9.01 %
3 Month Return
-43.25 %
1 Year Return
+ 163.51 %
3 Year Return
0 %
5 Year Return
0 %

Maze Therapeutics, Inc. Common Stock Stock Fundamentals & Key Indicators

Check Maze Therapeutics, Inc. Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.5B

EPS (TTM)

-2.7979

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-38.67%

Maze Therapeutics, Inc. Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Maze Therapeutics, Inc. Common Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Maze Therapeutics, Inc. Common Stock image
Maze Therapeutics, Inc. Common Stock
NA$1.5BNANA0.00%
Revolution Medicines Inc image
Revolution Medicines Inc
BUY$31.8B357.47%NA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.2B112.69%73.5512.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$115.0B104.13%26.8935.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.7B36.84%17.3929.65%

Stock Returns calculator for Maze Therapeutics, Inc. Common Stock Stock including INR - Dollar returns

The Maze Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Maze Therapeutics, Inc. Common Stock investment value today

Current value as on today

₹2,85,536

Returns

₹1,85,536

(+185.54%)

Returns from Maze Therapeutics, Inc. Common Stock Stock

₹1,52,577 (+152.58%)

Dollar Impact

₹32,959 (+32.96%)

Indian Investors' Interest in Maze Therapeutics, Inc. Common Stock Stock

Search interest for Maze Therapeutics, Inc. Common Stock Stock has decreased by -71% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-71% versus previous 30 day period

Maze Therapeutics, Inc. Common Stock Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
-
-
165
2
-
-
-
-
-
20
Gross Profit
0
0
165
2
0
0
0
-
0
19
Operating Income
-23
-28
139
-24
-29
-35
-36
-32
-38
-26
EBITDA
-22
-27
140
-23
-29
-34
-33
-29
-37
-26
Interest Expense
-
-
-
-
-
-
-
-
-
0
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-26
-32
140
-25
-29
-32
-33
-30
-34
-24
Income Tax Expense
-
-
1
0
0
-
-
-
-
-
Net Income
-26
-32
139
-24
-29
-32
-33
-30
-34
-24
Net Profit Margin
0.00%
0.00%
84.28%
-990.08%
0.00%
0.00%
0.00%
0.00%
0.00%
-121.04%

Maze Therapeutics, Inc. Common Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
167
-
Gross Profit
-3
-4
167
-2
Operating Income
-111
-98
57
-142
EBITDA
-107
-94
60
-140
Interest Expense
-
-
-
-
Depreciation
3
4
3
2
Income Before Tax
-114
-100
53
-131
Income Tax Expense
-
-
1
-
Net Income
-114
-100
52
-131
Net Profit Margin
0.00%
0.00%
31.18%
0.00%

Maze Therapeutics, Inc. Common Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-32
139
-24
-29
-32
-33
-30
-34
-24
Operating Cash Flow
-23
145
-23
-22
-29
-30
-24
-27
-39
Investing Cash Flow
0
0
0
0
0
0
-66
-103
6
Financing Cash Flow
24
0
-2
70
127
0
143
3
42
Change in Cash
0
145
-25
47
97
-29
52
-127
9

Maze Therapeutics, Inc. Common Stock Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Dec 2025
Net Income
-100
52
-131
Operating Cash Flow
-86
75
-111
Investing Cash Flow
0
-1
-170
Financing Cash Flow
16
92
275
Change in Cash
-70
167
-7

Insights on Maze Therapeutics, Inc. Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 264.8% return, outperforming this stock by 101.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, MAZE stock has moved down by -43.3%

About Maze Therapeutics, Inc. Common Stock

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
OrganisationMaze Therapeutics, Inc. Common Stock
Headquarters171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
IndustryBiotechnology
CEODr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
E-voting on sharesClick here to vote

Key Management of Maze Therapeutics, Inc. Common Stock

Name

Title

Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.

CEO & Director

Mr. Misbah Tahir CPA

Chief Financial Officer

Mr. Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Ms. Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Mr. Maarten Hoek

Senior Vice President of Research

Dr. Harold S. Bernstein M.D., Ph.D.

President of Research & Development and Chief Medical Officer

Ms. Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Mr. Matt Krause

Senior Vice President of Human Resources

Mr. Atul Dandekar

Chief Strategy & Business Officer

Ms. Amy Bachrodt

Senior Vice President of Finance

FAQs

What is Maze Therapeutics, Inc. Common Stock share price today?

Maze Therapeutics, Inc. Common Stock share price today is $24.5 as on at the close of the market. Maze Therapeutics, Inc. Common Stock share today touched a day high of $25.75 and a low of $24.16.

What is the 52 week high and 52 week low for Maze Therapeutics, Inc. Common Stock share?

Maze Therapeutics, Inc. Common Stock share touched a 52 week high of $53.65 on and a 52 week low of $9.16 on . Maze Therapeutics, Inc. Common Stock stock price today i.e. is closed at $24.5,which is 54.33% down from its 52 week high and 167.61% up from its 52 week low.

What is Maze Therapeutics, Inc. Common Stock's market capitalisation today?

Maze Therapeutics, Inc. Common Stock market capitalisation is $0.00T as on .

How to invest in Maze Therapeutics, Inc. Common Stock Stock (MAZE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Maze Therapeutics, Inc. Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Maze Therapeutics, Inc. Common Stock Shares that will get you 0.0612 shares as per Maze Therapeutics, Inc. Common Stock share price of $24.5 per share as on May 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Maze Therapeutics, Inc. Common Stock Stock (MAZE) from India?

Indian investors can start investing in Maze Therapeutics, Inc. Common Stock (MAZE) shares with as little as ₹96.5325 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹965.33 in Maze Therapeutics, Inc. Common Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on Maze Therapeutics, Inc. Common Stock share’s latest price of $24.5 as on May 19, 2026 at 8:46 am IST, you will get 0.4082 shares of Maze Therapeutics, Inc. Common Stock. Learn more about fractional shares .